Shionogi & Co., Ltd.
Stock Price Chart
2026/11/20 13:29 UpdatedPrice Trend
2026/11/20 13:29 UpdatedPrice & Trading Details
2026/11/20 13:29 UpdatedPRICE
TRADING
Analyst Recommendations 12 analysts
Updated 2026/11/01Earnings Calendar
Updated 2026/11/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/10/28 | ¥43.61 | ¥25.66 | -41.2% |
| 2026/08/03 | ¥46.90 | ¥114.81 | +144.8% |
| 2026/01/29 | ¥68.45 | ¥87.76 | +28.2% |
| 2025/10/27 | ¥50.55 | ¥51.93 | +2.7% |
Shareholder Composition
Updated 2026/11/01Top Mutual Funds / ETFs
Updated 2026/11/01Major Holders
Updated 2026/11/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund
|
21.4M | +4.83% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
11.1M | +1.15% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
7.4M | +1.24% | |
|
HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.
|
6.1M | -1.67% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
5.7M | +1.90% | |
|
John Hancock Funds III-International Growth Fund
|
3.5M | 0.00% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
535.8K | +15.21% |
Dividend History 3Years Growth
Updated 2026/11/22| Year | Dividend | Change |
|---|---|---|
| 2027 In Progress | ¥40 | - |
| 2026 | ¥71 | +15.8% |
| 2025 | ¥61 | +15.0% |
| 2024 | ¥53 | +18.5% |
| 2023 | ¥45 | - |
Financial Performance
2026/11/22 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥335,138M | ¥426,684M | ¥435,081M | ¥438,268M |
| Gross Profit | ¥279,722M | ¥364,437M | ¥377,479M | ¥374,441M |
| Operating Income | ¥110,312M | ¥149,004M | ¥153,312M | ¥156,604M |
| Pretax Income | ¥127,109M | ¥224,832M | ¥204,984M | ¥209,777M |
| Net Income | ¥114,185M | ¥184,965M | ¥162,030M | ¥170,435M |
| EPS | ¥126.21 | ¥207.03 | ¥186.11 | - |
| Operating Margin | 32.92% | 34.92% | 35.24% | 35.73% |
| Balance Sheet | ||||
| Total Assets | ¥1,150,601M | ¥1,311,800M | ¥1,416,918M | ¥1,535,349M |
| Total Equity | ¥975,661M | ¥1,100,046M | ¥1,235,325M | ¥1,361,924M |
| Total Liabilities | ¥174,940M | ¥211,754M | ¥181,593M | ¥173,425M |
| Cash | ¥254,420M | ¥309,224M | ¥358,090M | ¥374,795M |
| Interest-bearing Debt | ¥6,674M | ¥9,411M | ¥11,620M | ¥21,882M |
| Equity Ratio | 84.80% | 83.86% | 87.18% | 88.70% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.02 |
| Cash Flow | ||||
| Operating CF | ¥102,068M | ¥177,867M | ¥154,284M | ¥195,460M |
| Investing CF | -¥96,204M | -¥48,292M | ¥5,922M | -¥116,080M |
| Financing CF | -¥36,615M | -¥84,123M | -¥126,853M | -¥64,908M |
| Free CF | ¥70,504M | ¥140,680M | ¥126,017M | ¥143,357M |
| Efficiency | ||||
| ROE | 11.70% | 16.81% | 13.12% | 12.51% |
| ROA | 9.92% | 14.10% | 11.44% | 11.10% |
Latest IR Information
-
Completion of Full Acquisition of U.S. IntraBio, Inc.
Announced completion of acquisition of IntraBio. Through expansion of the AQNEURSA neurological treatment portfolio and strengthening global capabilities in rare diseases, the company will expand its clinical development and commercial base in rare disease areas.
Read more -
Correction: Financial Summary for the Six-Month Period Ended March 2027 (IFRS, Consolidated) - Correction Notice
Published corrections to parts of the financial summary for the six-month period ended March 2027. Corrections relate to cash flow figures and adjustments to the calculation of dividends received from equity-method affiliates. Key financial items, including the balance and change...
Read more -
Partial Correction to "Quarterly Financial Summary [IFRS] (Consolidated)"
Announced corrections to the Q1 financial summary for the fiscal year ending March 2027. Revised descriptions and certain figures related to cash flows. Revised operating cash flow is 46,318 million yen, and corrected items include equity-method dividend receipts and matters...
Read more -
Borrowing of a Bridge Loan in Connection with the Acquisition of IntraBio Inc.
In connection with making IntraBio Inc. a wholly owned subsidiary, Shionogi & Co., Ltd. borrowed a 3,000 hundred million yen bridge loan from Sumitomo Mitsui Banking Corporation. The agreement date and execution date are both 2026-11-10. The final repayment date...
Read more -
Correction / Numeric Data Correction: "Notice of Revision to Earnings Guidance and Annual Dividend Forecast for the Fiscal Year Ending March 31, 2027 (Dividend Increase)"
Revised upward the consolidated earnings guidance for the fiscal year ending March 31, 2027 (including a dividend increase). Revenue up +2.9% from previous forecast, operating income +4.5%, net income attributable to owners of parent +1.2%, etc. Also includes a revision...
Read more
Latest News (5 items)
-
Average Analyst Rating: buy
Average Target Price: ¥3,355
Rating Score: 2.27 (Based on 12 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. It is also involved in consumer healthcare business; manufacturing, sale, analytical testing, and pharmaceutical engineering of medicinal drugs and investigational drugs; contracted monitoring of epidemiological components in sewage; promotion of implementation in social infrastructure; and business related to providing data and information; develops and sells foothold; and research and development of mucosal vaccines. In addition, the company provides contract support services for experimental research; contract testing of agricultural production materials; solutions for education and healthcare, system development, human resource development, and training business; marketing support services; and IT services for medical and healthcare-related issues. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. The company was founded in 1878 and is headquartered in Kita, Japan.